Board Disclosures

The leadership of Bladder Cancer has disclosed the following information in keeping with the journal's disclosure policy.

Seth P. Lerner, MD, Editor-in-Chief
Advisory Board: FerGene, Pfizer
Consultant: Genentech, UroGen, Vaxiion, Merck, QED Therapeutics, Verity
Clinical Trials: Genentech (SWOG), UroGen, Vaxiion, Endo, FKD, JBL (SWOG), Viventia
Licenses/Patents: TCGA Classifier
Other: UroToday (honoraria), IOS Press (editorial responsibilities, compensated), co-editor bladder cancer section UpToDate

Dan Theodorescu, MD, PhD, Editor-in-Chief
Consultant: Machavert, Merck, Urogen
Honoraria: Machavert, Merck, Urogen
Licenses/Patents: University of Colorado
Research Support: Medivation/Astellas
Stockholder in: Aurora Oncology, PrecisionProfile
Other: IOS Press (editorial responsibilities, compensated)

Piyush K. Agarwal, MD, Associate Editor
Advisory Board (unpaid): AstraZeneca

Joaquim Bellmunt, MD, PhD, Associate Editor
Consultant or Advisory Role: Pierre Fabre, Astellas Pharma, Pfizer, Merck, Genentech, Novartis, AstraZeneca/MedImmune, Bristol-Myers Squibb
Research Funding: Millennium, Sanofi, Pfizer/EMD Serono
Stocks: Rainier
Travel, Accommodations, Expenses: Pfizer, MSD Oncology, Ipsen

David J. DeGraff, PhD, Associate Editor
Nothing to disclose

Lars Dyrskjøt, PhD, Associate Editor
Consultant: Ferring
Clinical Trials: Roche
Other Research Support: C2i Genomics, Natera, Ferring, AstraZeneca

Jason A. Efstathiou, MD, PhD, Associate Editor
Consultant: Blue Earth Diagnostics, Taris Biomedical
Scientific Advisory Board: Blue Earth Diagnostics, Janssen, Bayer Healthcare Pharmaceuticals

Bishoy M. Faltas, MD, Associate Editor
Honoraria: Springer Nature, UroToday
Clinical Trials: Eli-Lilly

Matthew Galsky, MD, Associate Editor for Reviews
Consultant or Advisory Role: BioMotiv, Janssen, Dendreon, Merck, GlaxoSmithKline, Lilly, Astellas Pharma, Genentech, Bristol-Myers Squibb, Novartis, Pfizer, EMD Serono, AstraZeneca, Seattle Genetics, Incyte, Aileron Therapeutics, Dracen, Inovio Pharmaceuticals, NuMab, Dragonfly Therapeutics
Research Funding: Janssen Oncology, Dendreon, Novartis, Bristol-Myers Squibb, Merck, AstraZeneca, Genentech/Roche 
Stock and Other Ownership Interests: Rappta Theraputics

Donna Hansel, MD, PhD, Associate Editor
Consultant: AstraZeneca, Merck, Janssen
Other Research Support: Konica Minolta
Other: Genentech, AstraZeneca, Taris

Arndt Hartmann, MD, Associate Editor
Advisory Board: BMS, MSD, Roche, Cepheid, Qiagen, Janssen, Astra Zeneca, Agilent, Lilly, Phäon
Consultant: BMS, MSD, Roche, Astra Zeneca, Novartis, Boehringer Ingelheim, Abbvie, Cepheid, Nanostring, Illumina, Qiagen, Biontech, Janssen, 3D Histotech, Diaceutics
Clinical Trials: Janssen, Cepheid, AstraZeneca, Roche
Speaker Honoraria: BMS, MSD, Roche, Astra Zeneca, Boehringer Ingelheim, Abbvie, Janssen, Pfizer
Other Research Support: Illumina, Cepheid, Biotech, Roche, Janssen, Nanostring AstraZeneca

Anne Kiltie, MA, DM, DSc, Associate Editor
Research Grant Funding: CRUK, UCARE

Yair Lotan, MD, Associate Editor
Consultant or Advisory Role: Photocure, Astra-Zeneca, Merck, Vessi Medical, Radera, CAPs Medical, Ferring Research, Fergene, Abbvie, Cleveland Diagnostics , Synergo (ended Mar 2020), Urogen (ended Mar 2020)
Clinical Trial or Scientific Study: Abbott (completed Mar 2019), Biocancell (ended Jan 2020), Cepheid, Pacific Edge, FKD, MDxHealth, GenomeDx Biosciences Inc., Photocure

S. Bruce Malkowicz, MD, Associate Editor
Consultant: Pacific Edge
Clinical Trial Investigator: Merck

Surena F. Matin, MD, Associate Editor
Consultant: QED Therapeutics, Urogen (ended Jan 2019)
Advisory Board: Taris Bio
Other Research Support: AT&T Foundation, Specialized Program in Oncology Research (SPORE)

David McConkey, PhD, Associate Editor
Grant Support: Astra-Zeneca, Rainier Pharmaceuticals
Honoraria: Janssen, H3 Biomedicine, Rainier Pharmaceuticals

Edward M. Messing, MD, Associate Editor
Nothing to disclose

Matt Milowsky, MD, Associate Editor
Research funding: Merck, Roche/Genentech, Bristol-Myers Squibb, Seattle Genetics, Astellas Pharma, Clovis Oncology, Inovio Pharmaceuticals, AstraZeneca, Mirati Therapeutics, Constellation Pharmaceuticals, Syndax, MedImmune, Incyte
Other Relationship: Asieris

Francisco X. Real, MD, PhD, Associate Editor
Speaker Honoraria: Roche
Other Research Support: Boehringer-Ingelheim, VCN Biosciences

Bas W.G. van Rhijn, MD, PhD, Associate Editor
Research Funding: Maurits and Anna de Kock Foundation, Dutch Cancer Society, EAU, SN-BLADDER 2016 (M14HSN), NABUCCO, Pre-PREVENCYS 2019, MIBC II-ON 2020, Bristol-Myers-Squibb
Sponsored Lecture: GU Masterclass Den Dolder, NL – Neoadjuvant chemotherapy in MIBC; Sponsored by Roche and BMS (Sep 2018)
European Advisory Board Meeting: Ferring on trials in NMIBC (Dec 2018, Amsterdam, NL)
Scientific Advisory Committee: QED Therapeutics

Gottfrid Sjödahl, Ph.D. Associate Editor
Nothing to disclose

Mark S. Soloway, MD, Associate Editor
Nothing to disclose

Cora N. Sternberg, MD, Associate Editor
Consultant: Pfizer, Merck, AstraZeneca, Astellas Pharma, Sanofi-Genzyme, Roche/Genentech, Incyte, Medscape, Clovis Oncology, UroToday, MSD

Robert Svatek, MD, Associate Editor
Consultant: FerGene
Clinical Trials: JBL (SWOG), FKD

George Thalmann, MD, Associate Editor
Clinical Trials: Cancer Sniff Dogs (bladder cancer)
Other Research Support: Peer-reviewed funding agencies

Xue-Ru Wu, MD, Associate Editor
Nothing to disclose

Diane Zipursky Quale, BA, JD, Associate Editor
Nothing to disclose

Alexandre R. Zlotta, MD, PhD, Associate Editor
Consultant: AstraZeneca, Ferring, Janssen, Sanofi, Verity Pharma

Last updated: Aug 31, 2020